Compare Monster Beverage Corp (MNST) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs TransMedics Group Inc — how do they compare? Monster Beverage Corp trades at $42.97 (market cap $84.53B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Monster Beverage Corp is far larger — about 27.6× TransMedics Group Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| MNST | TMDX | |
|---|---|---|
Market Cap | $84.53B | $3.06B |
Sector | Consumer Staples | Technology |
52-Week High | $49.97 | $150.42 |
52-Week Low | $31.41 | $61.99 |
Enterprise Value | $82.83B | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.15, down 1.53% on the day, following a recent 2-for-1 stock split completed August 11, 2026. The stock shows strong fundamental performance with revenue growing from $6.3B in 2022 to $8.3B in 2025, while net income expanded to $1.91B. Technical indicators present a mixed picture with bullish oscillators but bearish moving averages, creating uncertainty in the near-term direction. Analyst consensus remains positive with 51% buy ratings and a $51.10 price target representing 18% upside potential.
MNST offers compelling growth prospects driven by 20%+ revenue growth and expanding international presence (46% of Q2 2026 sales). However, elevated valuation multiples (P/E 39.95, P/S 9.24) and rising cost pressures present risks. The company's consistent earnings beats and strong cash flow generation support the bullish case, but investors should weigh growth potential against premium valuation in a competitive beverage market.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
